Related Experiment Video
Updated: Jun 9, 2026

Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy
Published on: November 29, 2018
Immune-related gigantomastia: a case study
Alessia Lozito1, Maria Gemelli2, Donata Micello3
1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, 20090, Italy.
Immune checkpoint inhibitors, like PD-1/PDL-1 blockers, can cause immune-related adverse events. This report details a rare case of gigantomastia potentially linked to this cancer immunotherapy.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors represent a significant advancement in cancer therapy, particularly for lung cancer.
- While effective, these immunotherapies can induce immune-related adverse events (irAEs), posing management challenges.
- Gigantomastia, a rare condition of excessive breast growth, has been linked to certain medications, but not previously to immunotherapy.
More Related Videos
13:35Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
Published on: May 17, 2024
07:25Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research
Published on: October 13, 2023
Related Concept Videos
Graves' Disease I: Introduction
Cirrhosis I: Introduction